450 Studies Now Enrolling
Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III
Study of Therapy to Assess if it Reduces Risk of Cardiac Dysfunction in Patients with Breast Cancer
| Sponsor: | NIH |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAR6417 |
| Contact: | Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
Additional Study Information:
To assess whether prophylactic beta blocker therapy with carvedilol compared with no intervention reduces the risk of subsequent cardiac dysfunction in patients with metastatic breast cancer receiving trastuzumab-based HER-2 targeted therapy.
This study is closed
